Ipamorelin research monograph — the selective ghrelin-mimetic GH secretagogue

Ipamorelin is one of the most-discussed growth-hormone-secretagogue peptides,
usually praised for its selectivity. This monograph covers what that selectivity
means and what the evidence base looks like.

Chemical identity & structure.
Ipamorelin is a synthetic pentapeptide (five amino acids). It belongs to the
class of growth hormone secretagogues that act as ghrelin mimetics — that is,
it activates the growth hormone secretagogue receptor (GHS-R), the same receptor
the natural hormone ghrelin acts on. It is a small, defined peptide, which makes
identity and purity verification straightforward.

Mechanism of action.
By agonizing the GHS-R, ipamorelin stimulates the pituitary to release growth
hormone in a pulse. Its notable feature, repeatedly reported in the literature,
is selectivity: compared with older secretagogues, ipamorelin stimulates GH
release with minimal effect on cortisol and prolactin. Because it acts upstream —
prompting the pituitary's own release rather than supplying GH directly — its
effect is constrained by the body's own regulatory feedback, unlike
administration of hGH itself.

Key research findings.
Ipamorelin was originally developed by a pharmaceutical company and entered
early clinical research before its development was discontinued for business
rather than safety reasons. The available literature — early clinical and
preclinical — documents reliable, relatively clean GH-release stimulation. There
is no large modern outcome trial program.

The research / citation base.
Ipamorelin is not an approved drug. Its evidence base is early clinical and
preclinical research from its original development era plus subsequent
preclinical work. It is well-characterized pharmacologically but not supported
by large efficacy trials for any specific outcome.

Research protocols in the literature.
Research has used subcutaneous administration of reconstituted lyophilized
peptide. Because GH secretion is pulsatile, the literature often discusses
ipamorelin in the context of pulse timing, and it is frequently studied
alongside a GHRH analog (such as CJC-1295) on the rationale that the two act
through complementary pathways.

Quality & sourcing notes.
As a small pentapeptide, ipamorelin should carry a batch-specific COA with mass-
spectrometry identity and HPLC purity (≥98% is a reasonable expectation). A
common market problem is mislabeling — verify that the vial contains ipamorelin
and not a cheaper substitute secretagogue.

*Research-use note: Educational summary of published research. Ipamorelin is not
an approved drug; this is research context only and not medical advice.*